Quarterly report [Sections 13 or 15(d)]

Note 7 - Stockholder's Equity (Tables)

v3.25.2
Note 7 - Stockholder's Equity (Tables)
6 Months Ended
Jun. 30, 2025
Notes Tables  
Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]
   

Number of

   

Weighted

 
   

Units and

   

Average Grant

 
   

Awards

   

Date Fair Value

 

Unvested balance at December 31, 2024

    236,028     $ 3.44  

Vested

    (284 )     85.50  

Unvested balance at March 31, 2025

    235,744     $ 3.34  

Forfeited

    (212 )     171.94  

Unvested balance at June 30, 2025

    235,532     $ 3.19  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
                   

Weighted

         
                   

Average

         
         

Weighted

   

Remaining

   

Aggregate

 
   

Number

   

Average

   

Contractual

   

Intrinsic Value

 
   

of Options

   

Exercise Price

   

Term (years)

   

(in thousands)

 

Outstanding at December 31, 2024

    256,474     $ 9.74       9.6     $  

Outstanding at Balance at June 30, 2025

    256,474     $ 9.74       9.1     $  

Expected to vest

    166,125     $ 7.52       9.1     $  

Exercisable

    90,349     $ 13.81       9.2     $  
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
   

For the Three Months Ended

   

For the Six Months Ended

 
   

June 30,

   

June 30,

 
   

2025

   

2024

   

2025

   

2024

 

Research and development

  $ 31     $ 45     $ 71     $ 90  

General and administrative

    144       147       289       293  

Total stock-based compensation expense

  $ 175     $ 192     $ 360     $ 383  
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
           

Weighted

         
           

Average

   

Aggregate

 
           

Exercise

   

Intrinsic Value

 
   

Warrants

   

Price

   

(in thousands)

 

Outstanding, December 31, 2024

    1,476,200     $ 8.64     $  

Outstanding, June 30, 2025

    1,476,200     $ 8.64     $